Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Xeris Biopharma Holdings, Inc.
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
March 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
March 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
February 28, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
February 05, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
January 10, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 05, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Updates Its Outlook for 2023
January 04, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
October 16, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
September 27, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris to Participate in the 2023 Cantor Global Healthcare Conference
September 14, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023
August 01, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Ships One Millionth Gvoke® Unit
July 31, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism
June 21, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Participate at the Jefferies Healthcare Conference
June 01, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Reports First Quarter 2023 Financial Results
May 09, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023
May 02, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations
April 18, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™
March 30, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
March 08, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023
February 23, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®
January 30, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Updates Its Outlook For 2022
January 05, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism
December 15, 2022
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.